Skip to Main Content

Author Details

Ronny Drapkin
University of Pennsylvania School of Medicine
1980
191
65
PMIDPaper TitleJournal TitlePublished Year
38048050Aneuploidy Landscape in Precursors of Ovarian Cancer.Clin Cancer Res2024
38048050Aneuploidy Landscape in Precursors of Ovarian Cancer.Clin Cancer Res2024
36707610LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.Sci Rep2023
36446254Targeting NaPi2b in ovarian cancer.Cancer Treat Rev2023
37841875Dual blockade of BRD4 and ATR/WEE1 pathways exploits <i>ARID1A</i> loss in clear cell ovarian cancer.Res Sq2023
37864274Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors.Genome Biol2023
37345659H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.JCI Insight2023
37090516Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development.bioRxiv2023
36963401Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.Cancer Cell2023
36707610LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.Sci Rep2023
36747644Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker.bioRxiv2023
37163587Functional neuronal circuits promote disease progression in cancer.Sci Adv2023
37097611Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.Clin Cancer Res2023
37864274Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors.Genome Biol2023
37841875Dual blockade of BRD4 and ATR/WEE1 pathways exploits <i>ARID1A</i> loss in clear cell ovarian cancer.Res Sq2023
37090516Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development.bioRxiv2023
37345659H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.JCI Insight2023
37097611Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.Clin Cancer Res2023
37163587Functional neuronal circuits promote disease progression in cancer.Sci Adv2023
36963401Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.Cancer Cell2023
36446254Targeting NaPi2b in ovarian cancer.Cancer Treat Rev2023
36747644Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker.bioRxiv2023
34697060DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Cancer Epidemiol Biomarkers Prev2022
35380877The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.Sci Signal2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
35434236A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.Gynecol Oncol Rep2022
36214625Cell Competition in Carcinogenesis.Cancer Res2022
36323780Nociceptor neurons affect cancer immunosurveillance.Nature2022
35726891KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.Cancer Immunol Res2022
36509990L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary.Commun Biol2022
34697060DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Cancer Epidemiol Biomarkers Prev2022
35380877The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.Sci Signal2022
35434236A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.Gynecol Oncol Rep2022
35726891KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.Cancer Immunol Res2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
36509990L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary.Commun Biol2022
36214625Cell Competition in Carcinogenesis.Cancer Res2022
36323780Nociceptor neurons affect cancer immunosurveillance.Nature2022
33361393Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers.Cancer Res2021
33753553Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.Mol Cancer Res2021
34060481Tumor innervation: peripheral nerves take control of the tumor microenvironment.J Clin Invest2021
33890574Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer.Elife2021
33773808Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.Gynecol Oncol2021
33561012Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.J Clin Invest2021
34085048Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.Nat Cancer2021
33755733Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models.J Clin Endocrinol Metab2021
33361393Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers.Cancer Res2021
33430180Cell Fitness: More Than Push-Ups.Int J Mol Sci2021
34622231<i>CCNE1</i> copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models.Cell Rep Med2021
34620496Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.Gynecol Oncol2021
  • 1 - 50 of 382

Recommended Authors

Amy Lum
University of British Columbia
Career Start Year 2014
Number of shared co-authors 62
Myriam Kossai
INSERM, Universite Clermont Auvergne
Career Start Year 2008
Number of shared co-authors 1
Ruby Yun-Ju Huang
National Taiwan University College of Medicine
Career Start Year 2008
Number of shared co-authors 60
Yingmei Wang
Tianjin Medical University General Hospital
Career Start Year 2007
Number of shared co-authors 4
Divya Gupta
Emory University School of Medicine
Career Start Year 2006
Number of shared co-authors 1
Stefan Kommoss
Eberhard Karls University Tubingen
Career Start Year 2005
Number of shared co-authors 80
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 61
Brigitte L Th??riault
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2004
Number of shared co-authors 2
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 25
Sven Mahner
University Hospital
Career Start Year 2002
Number of shared co-authors 62
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 18
Blaise A Clarke
University of Toronto.
Career Start Year 2001
Number of shared co-authors 35
Aparna A Kamat
Houston Methodist Hospital
Career Start Year 2000
Number of shared co-authors 3
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 20
Susan C Modesitt
University of Virginia, Emily Couric Clinical Cancer Center
Career Start Year 1998
Number of shared co-authors 4
Michael E Carney
John A. Burns School of Medicine, University of Hawaii
Career Start Year 1995
Number of shared co-authors 87
Janine Senz
University of British Columbia
Career Start Year 1994
Number of shared co-authors 68
Yong-Man Kim
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1994
Number of shared co-authors 1
Denise C Connolly
Fox Chase Cancer Center
Career Start Year 1993
Number of shared co-authors 10
Naveena Singh
Barts Health NHS Trust
Career Start Year 1993
Number of shared co-authors 66
George L Maxwell
Women's Health Integrated Research Center, Inova Health System
Career Start Year 1992
Number of shared co-authors 49
Rosemarie Schmandt
The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 7
Gustavo C Rodriguez
Clinica Quirurgica 2 (Surgical Clinic 2), Hospital Maciel
Career Start Year 1990
Number of shared co-authors 80
Kathleen M Darcy
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Career Start Year 1990
Number of shared co-authors 40
Lora H Ellenson
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 6
Cyril B Gilks
University of British Columbia
Career Start Year 1987
Number of shared co-authors 77
Gary L Keeney
Mayo Clinic
Career Start Year 1984
Number of shared co-authors 73
Andrew D Cherniack
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 44
Jos?? Palacios
Universidad de Alcala
Career Start Year 1983
Number of shared co-authors 67
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 3

Collaborators

Christopher P Crum
Co-authored papers 18
Danny Reinberg
HHMI/NYU Langone School of Medicine
Co-authored papers 13
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 12
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 11
Michael J Birrer
Co-authored papers 10
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 9
Douglas A Levine
Perlmutter Cancer Center
Co-authored papers 8
Keren Levanon
Co-authored papers 8
Victor E Velculescu
Co-authored papers 7
Dariush Etemadmoghadam
Peter MacCallum Cancer Centre
Co-authored papers 7
Joan S Brugge
Co-authored papers 6
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 6
David G Huntsman
University of British Columbia
Co-authored papers 6
Sekhar Duraisamy
Co-authored papers 6
Anna DeFazio
Westmead Hospital
Co-authored papers 6
Andrew V Kossenkov
The Wistar Institute
Co-authored papers 6
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 6
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 5
Anil K Sood
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Ernst Lengyel
University of Chicago
Co-authored papers 5
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 5
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 5
Matthew Meyerson
Broad Institute
Co-authored papers 4
Steven J Skates
Co-authored papers 4
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 4
Euihye Jung
Penn Ovarian Cancer Research Center, University of Pennsylvania
Co-authored papers 4
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 4
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Co-authored papers 4
Euan A Stronach
Imperial College London
Co-authored papers 4
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 4
Release 1.2